

Report

TOP TRENDS IN LIFE SCIENCES 2026

SUMMARY

[Download
the full report](#)

■ ■ ■ | D Z P

1 | Wstęp

Dr Mateusz Mądry, Partner, Head of the Life Sciences Practice, DZP

Many of the discussions during **the second Top Trends in Life Sciences conference** led to a similar conclusion – regulations in the pharmaceutical sector are now increasingly linked to the broader debate on competitiveness, health security and innovation in Europe.

In this year's event, **nearly 200 people took part** – representatives of pharmaceutical companies, public administration bodies and industry organisations.

I am delighted that Top Trends in Life Sciences, an event organised by the **Domański Zakrzewski Palinka** Law Firm (DZP), provides a forum for an exchange of views among business representatives, regulators and industry experts.

I would like to thank all the speakers and participants for the insightful discussions.

Dr Mateusz Mądry

Partner, Head of the Life Sciences Practice | DZP Law Firm



SUMMARY

Key takeaways from each section of the event:

Competitiveness of the EU pharmaceutical market:

- During a speech, it was pointed out that the European Union has one of the most developed regulatory systems in the world ensuring a high level of patient safety. However, maintaining the sector's global competitiveness will require greater regulatory predictability and a further reduction in the fragmentation of the internal market.

Legislative changes and the future of the medicinal products registration system:

- Experts discussed the key legislative initiatives affecting the EU's medicines registration system. Particular attention was paid to the draft Biotech Act, measures aimed at reducing medicine shortages and changes to the regulations on clinical trials, which could help improve cooperation between trial sponsors and regulators and shorten the time taken to approve trials.

European Health Data Space (EHDS):

- The implementation of the European Health Data Space could significantly increase the use of health data in trials and the development of new treatments. However, experts stressed that it is crucial for transparent rules on data access to be developed and for a high level of patient privacy protection to be ensured.

The future of regulation in the pharmaceutical sector:

- The panel discussion on trends in pharmaceutical law provided an opportunity for representatives of regulatory bodies, the business sector and industry experts to exchange views. The discussion focused on improving the efficiency of regulatory processes, adapting regulations to dynamic market changes, and the role of new technologies in the transformation of the life sciences sector.

Legal and business challenges facing the life sciences sector:

- During the conference, DZP experts discussed a range of practical issues relevant to the sector. The discussions covered, e.g. regulations on packaging in the pharmaceutical sector, access to the public procurement market, tax challenges relating to transfer pricing and withholding tax, and opportunities for financing innovation through venture capital. Other topics covered included upcoming changes to employment law, new standards in legal communication (legal design) and the challenges associated with implementing AI governance systems in organisations in the life sciences sector.



■ ■ ■ | **DZP**

more than law

PATRONS

